The CCL7 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CCL7 gene in the human A-549 lung carcinoma epithelial cell line. This loss-of-function model enables investigation of CCL7-mediated chemokine signaling and its roles in inflammatory and tumor microenvironments without introducing defined clonal genotypes. The polyclonal format retains population-level heterogeneity while eliminating functional CCL7 expression, providing a robust platform for studying gene-dependent phenotypes in a relevant pulmonary epithelial context.
The host A-549 cell line was established from a 58-year-old Caucasian male with lung adenocarcinoma and serves as a widely used model for respiratory diseases, drug delivery, and cancer biology. These adherent epithelial cells exhibit characteristic features of type II alveolar epithelium and are permissive for studying chemokine secretion, immune cell recruitment, and inflammatory responses in vitro. The A-549 background offers a well-characterized system for examining how CCL7 knockout alters epithelial?Cimmune cross-talk and tumor-associated signaling networks.
CCL7 encodes monocyte chemotactic protein-3 (MCP-3), a potent chemoattractant for monocytes, lymphocytes, basophils, and eosinophils. It functions by binding to CCR1, CCR2, and CCR3, which couple to G-proteins and activate downstream effectors including PLCG1, calcium flux, and the MAPK1/MAPK3 and AKT1 kinase cascades. CCL7 expression is upregulated by pro-inflammatory mediators such as IL1B, TNF, IFNG, and NFKB1/RELA, and it interacts with glycosaminoglycans for localized presentation. Disruption of CCL7 impairs chemotactic recruitment of leukocytes via these receptors, thereby attenuating downstream calcium signaling, MAP kinase activation, and transcriptional programs that drive leukocyte transendothelial migration and cytokine production.
In the A-549 cellular context, CCL7 knockout eliminates an autocrine and paracrine chemokine signal implicated in modulating the tumor microenvironment and metastatic niche. This polyclonal knockout model allows researchers to dissect CCL7-dependent contributions to cancer cell invasion, immune evasion, and inflammatory exacerbation relevant to conditions such as asthma, rheumatoid arthritis, and atherosclerosis. By severing the CCL7?CCCR1/CCR2/CCR3 axis, the cells provide a tool to examine how loss of monocyte and lymphocyte recruitment influences epithelial homeostasis, drug response, and cross-talk with stromal components.
This CCL7 knockout product is suited for advanced research applications including transwell migration assays to quantify monocyte or lymphocyte chemotaxis, RT-qPCR and ELISA to confirm loss of CCL7 mRNA and secreted protein, western blotting for protein expression analysis, and calcium flux assays to assess receptor signaling activity. It supports tumor microenvironment studies, inflammatory disease modeling, drug target validation, and CRISPR editing efficiency testing. Additional utility includes flow cytometric evaluation of chemokine receptor expression and multiplex cytokine profiling to map altered secretory networks. For further information or technical support, please contact Ascent Research.
